
The SWOG S1203 trial compared 7+3 and idarubicin (IA) regimens for induction therapy in acute myeloid leukemia (AML). Patients who did not achieve complete remission (CR) after the first cycle were eligible for a second cycle of the same regimen. CR rates were similar after the first and second courses of 7+3, while IA showed improved outcomes in the first cycle but lower success in the second.
Like
Save
Share